Thermo Fisher Scientific
TMO · What the business does, what can go wrong, and how options sellers approach it
What it does
Thermo Fisher Scientific supplies the tools and services that scientists and clinical labs use every day. Its products include analytical instruments, lab equipment, chemicals and reagents, diagnostic consumables, and contract research and manufacturing services.
Customers include pharmaceutical and biotech companies, hospitals and diagnostic labs, universities, government agencies, and industrial companies.
How it makes money
The company sells instruments (a one-time purchase), plus the consumables, reagents and service contracts that customers reorder as they run experiments and tests. That recurring portion tends to be steadier than equipment sales.
It also earns fees from outsourced work, such as running clinical trials for drug developers and manufacturing drugs on contract. Acquisitions have been a regular part of its strategy for adding products and capabilities.
Why investors own it
Investors often see it as a broad way to own the life sciences industry rather than a single drug or technology. Its products are used across many research and testing workflows, and its size gives it scale in distribution and customer relationships. Many holders like the mix of recurring consumables revenue and long-term demand for research and healthcare.
What can go wrong
- Biotech funding, pharma research budgets, and government and academic funding can tighten, slowing orders.
- Customers delay large instrument purchases when money is tight.
- Acquisitions can be expensive and hard to integrate.
- Testing demand can fall sharply once a surge, such as a pandemic, fades.
- Trade policy, currency moves and supply chain problems can affect costs and sales.
What to watch
- Organic revenue growth (excluding acquisitions and currency)
- Order trends and book-to-bill in instruments
- Operating margin and the company's annual guidance
- Free cash flow and its uses
- Contract research and manufacturing activity
Options income angle
Options on TMO are generally liquid, especially near-term contracts at strikes close to the current price.
Implied volatility tends to rise ahead of quarterly earnings and when research funding, drug-pricing policy or tariffs make headlines. Between those events implied volatility tends to ease.
One caution for premium sellers: earnings and guidance changes can cause a large one-day price gap. A covered call can cap upside after a jump, and a cash-secured put can leave you owning shares after a drop.
What the latest 10-K says
A plain-English read of the Risk Factors and Management's Discussion in the 10-K for the year ended December 31, 2025, filed February 26, 2026. Figures are as the filing reports them. Read the filing on SEC.gov
The filing in brief
Thermo Fisher Scientific reported revenues of $44,556 million, up 4% from $42,879 million, with organic growth (growth excluding acquisitions and currency effects) of 2%. Total debt rose to $39,384 million from $31,275 million as the company kept acquiring, including an agreement to acquire Clario Holdings, Inc. Academic and government demand and China were the weak spots.
How the business did
- Revenue and profit both rose. GAAP operating income was $7,746 million, with a margin of 17.4% versus 17.1%. GAAP diluted EPS was $17.74 versus $16.53, and adjusted EPS (a non-GAAP measure that excludes items such as acquisition amortization) was $22.87 versus $21.86.
- Pharma and biotech demand grew, partly offset by lower COVID-19 vaccine and therapy work. Academic and government revenue declined on U.S. customer hesitancy and conditions in China, and sales in China fell. Management credited "very strong productivity improvements" for the margin gain.
- Life Sciences Solutions revenue was $10,374 million, led by bioproduction. Analytical Instruments segment income fell to $1,736 million from $1,955 million, with margin at 23.0% versus 26.2%, mainly from tariffs and related foreign exchange effects.
- Operating cash flow was $7,818 million versus $8,667 million, and free cash flow (operating cash flow less net capital spending) was $6,337 million versus $7,324 million. The company repurchased $3.00 billion of stock and paid $0.64 billion in dividends.
- The GAAP tax rate of 7.5% was helped by several one-time deferred tax benefits, including $269 million tied to domestication transactions.
Risks specific to this company
- Debt: About $39.38 billion was outstanding. The $5.00 billion revolving credit facility requires a minimum interest coverage ratio of 3.5:1.0, and a breach could let lenders demand early repayment.
- Goodwill and intangibles: Goodwill is $49.36 billion and definite-lived intangibles are $14.60 billion. The newly acquired filtration and separation unit has $2.10 billion of goodwill, and its fair value was "not substantially in excess" of its $4.01 billion carrying value, so small shortfalls in results could trigger an impairment charge.
- Government-funded and China demand: Many customers depend on public budgets, and the filing notes the federal shutdown that began in October 2025. It also cites Chinese rules that favor local suppliers.
- Tariffs and trade: Many employees, suppliers and factories sit outside the U.S., and tariffs already hurt Analytical Instruments margins.
- Sole-source roles: The company is the sole manufacturer of a number of pharmaceuticals for customers, so a negative regulatory event could disrupt those customers. It also buys some materials from sole or limited suppliers.
- Liability: Its detection instruments are used at airports and border crossings, and a malfunction could bring claims that exceed insurance coverage.
What management is watching
- Tax rate: Management expects a 2026 GAAP effective tax rate between 7% and 9% and an adjusted rate of approximately 11.5%.
- Capital spending: Property, plant and equipment spending, net of disposals, is expected between $1.8 billion and $2.0 billion in 2026.
- Capital return and financing: The Board authorized up to $5.00 billion of buybacks on November 6, 2025. Early in 2026 the company repurchased $3.00 billion of stock, leaving $2.00 billion available at February 26, 2026. It also issued $3.80 billion of senior notes in the first quarter of 2026.
- Growth and cost plan: The growth strategy rests on high-impact innovation, trusted customer partnerships and the commercial engine. Restructuring charges of approximately $0.3 billion in 2025 are expected to yield annual savings of approximately $0.5 billion.
- Measures management points to: Organic revenue growth, adjusted operating income, adjusted EPS and free cash flow, all non-GAAP, which means they are not calculated under standard accounting rules.
What the latest 10-Q says
A plain-English read of Management's Discussion (and any new or changed risk factors) in the 10-Q for the quarter ended September 26, 2026, filed October 30, 2026. Figures are as the filing reports them. Read the filing on SEC.gov
The quarter in brief
Revenues were $12,137 million, up 9%, and organic growth (which strips out acquisitions, divestitures and currency) was 6%. Profit margins rose on productivity gains, including tariff refunds. The quarter also brought a large acquisition's contribution (Clario), the sale of the microbiology business and a $244 million held-for-sale loss.
How the business did
- Results: Quarterly revenues rose from $11,122 million to $12,137 million. Nine-month revenues were $35,136 million, up 9%, with organic growth of 4%. Adjusted earnings per share (EPS) were $6.68 versus $5.79, and GAAP diluted EPS was $4.64 versus $4.27.
- Margins: GAAP operating income margin was 18.6% versus 17.4%, and adjusted operating income margin was 24.5% versus 23.3%. Management credited "very strong productivity improvements, including tariff refunds realized," partly offset by strategic investments. GAAP results also included a $72 million gain on the microbiology sale, largely offset by the $244 million held-for-sale loss on a pharma services manufacturing facility.
- Segments: Laboratory Products and Biopharma Services revenues were $6,863 million, up 15%, with clinical research boosted by the Clario acquisition. Analytical Instruments segment income margin rose to 26.9% from 22.6%. Specialty Diagnostics revenues fell 6% to $1,098 million because of the microbiology sale, while organic revenues were flat. Pharma and biotech demand was very strong, and academic and government revenues were flat.
- Cash and capital return: Nine-month operating cash flow was $5,867 million, and free cash flow (operating cash flow less net capital spending) was $4,618 million versus $3,319 million. Acquisitions used $8.88 billion, and the company repurchased $4.00 billion of stock and paid $0.51 billion in dividends. Cash fell to $5,461 million from $9,852 million at December 31, 2025, and total debt was $41,370 million. Net interest expense for the quarter rose to $165 million from $113 million.
What management is watching
- Taxes: The company expects a 2026 GAAP effective tax rate between 9% and 11% and an adjusted rate of approximately 11.5%. Cash tax payments are expected to be approximately $1.5 billion because intangible asset amortization is not deductible for tax purposes.
- Spending: Property, plant and equipment spending for 2026 is expected to be between $1.9 billion and $2.0 billion. Strategic investments cover sales reach, e-commerce, marketing, service infrastructure and research and development.
- Capital and liquidity: $1.00 billion remained available under the $5.00 billion buyback authorization at October 30, 2026. Management believes cash, operating cash flow and its revolving credit facility will cover needs for at least the next 24 months.
- Measures to watch: Management points investors to organic revenue growth, adjusted operating income and margin, adjusted EPS and free cash flow. These exclude items such as acquisition-related amortization and restructuring costs.
Follow TMO in Kortex
The Kortex app shows TMO's price, options chain and IV rank, and answers your questions from live market data and SEC filings.
Free to download.
Learn the strategies
More stock briefs
For education only, not financial advice. Options involve risk and are not suitable for every investor.